neffy® adrenaline (epinephrine) nasal spray

The adrenaline device, neffy® is a needle-free nasal spray which has been approved for use for the treatment of anaphylaxis in both Europe and US.

The neffy® device is in the process of being approved for the Australian market through a partnership between CSL Seqirus and ARS Pharmaceuticals. ARS Pharmaceuticals is the developer of neffy® and CSL Seqirus is the Australian and New Zealand distributor. CSL Seqirus filed the drug with the Therapeutic Goods Administration (TGA) in December 2024, but the exact timeframe for availability to Australian patients is still being determined.

Allergy & Anaphylaxis Australia (A&AA) will continue to meet with CSL Seqirus and other key allergy stakeholders about neffy® and we look forward to the adrenaline nasal spray being registered with the TGA in Australia. Having a needle-free adrenaline option available in Australia will offer people at risk of anaphylaxis the ability to choose an adrenaline device that best suits their needs.